<DOC>
	<DOCNO>NCT00476554</DOCNO>
	<brief_summary>This open label , randomize phase II study design evaluate tolerability response rate high-dose low-dose regimen patient advance cutaneous T-cell lymphoma ( CTCL ) progressive , recurrent , persistent disease follow 2 systemic therapy .</brief_summary>
	<brief_title>A Randomized Phase II Study Oral Sapacitabine Patients With Advanced Cutaneous T-cell Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<criteria>Adult patient advance CTCL Have least 2 systemic therapy Must evaluable disease Eastern Cooperative Oncology Group performance status 02 Adequate bone marrow , hepatic renal function At least 3 week prior therapy Not receive topical steroid stable dose topical steroid least 2 week Able swallow capsule At least 3 week major surgery Agree practice effective contraception Able understand willing sign inform consent form Receiving systemic steroid Receiving topical systemic retinoids vitamin A Receiving radiotherapy , biological therapy , investigational agent Uncontrolled intercurrent illness Pregnant lactate woman Known HIVpositive Active hepatitis B and/or hepatitis C infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>CTCL</keyword>
</DOC>